This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
InMode (INMD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, InMode (INMD) closed at $45.21, marking a -0.09% move from the previous day.
InMode (INMD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
InMode (INMD) closed at $46.04 in the latest trading session, marking a +0.55% move from the prior day.
Investors Heavily Search InMode Ltd. (INMD): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching InMode (INMD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
InMode (INMD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, InMode (INMD) closed at $45.19, marking a -0.07% move from the previous day.
biote Corp. (BTMD) Moves 5.3% Higher: Will This Strength Last?
by Zacks Equity Research
biote Corp. (BTMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
3 Top-Tier Stocks Trading at Historical Discounts
by Ethan Feller
Hard to go wrong buying high quality stocks at a discount
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cellectar Biosciences, Inc. (CLRB) and InMode (INMD) have performed compared to their sector so far this year.
Is InMode (INMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how InMode (INMD) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare
by Zacks Equity Research
InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare are included in this Analyst Blog.
Solid Earnings Fuel Potential Bull Market in Medical Devices
by Indrajit Bandyopadhyay
CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.
Wall Street Analysts Think InMode (INMD) Could Surge 45.95%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 46% in InMode (INMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
InMode (INMD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
InMode (INMD) delivered earnings and revenue surprises of 4% and 0.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe InMode (INMD) Could Rally 33.66%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 33.7% upside potential for InMode (INMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
InMode (INMD) Soars 12.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
InMode (INMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
InMode (INMD) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.
Here's Why You Should Hold on to Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its progress with its three-legged strategic, which is driving growth and an impressive 2025 roadmap.
Cardiovascular Systems (CSII) Inks Deal to Enhance Patient Care
by Zacks Equity Research
Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.
CVS Health (CVS) Extends COVID-19 Antibody Testing Nationwide
by Zacks Equity Research
CVS Health's (CVS) antibody test detects for previous infection to COVID-19 and provides results within 15 minutes.
NuVasive's (NUVA) Simply Cervical Artificial Disc Gets FDA Nod
by Zacks Equity Research
NuVasive's (NUVA) Simplify Disc demonstrated an overall clinical success rate nearly 10% higher than the anterior cervical discectomy and fusion.
Medtronic (MDT) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Medtronic's (MDT) ventilator sales are robust and prospects of the Diabetes arm remain strong amid the pandemic.
Abbott's (ABT) DAPT for High Bleeding Risk Gets Europe Nod
by Zacks Equity Research
The studies by Abbott (ABT) show that DAPT can be safely discontinued early with no increased risk in patient adverse events.
Here's Why You Should Retain Abbott Laboratories (ABT) Stock
by Zacks Equity Research
Investors remain optimistic about Abbott Laboratories (ABT) owing to strong growth in its molecular and rapid diagnostics business and progress in diabetes arm.
Abbott's (ABT) BinaxNOW Test Gets FDA's EUA for Self Use
by Zacks Equity Research
According to Abbott (ABT), the self-test BinaxNOW together with vaccines will help Americans get back to their regular daily work with greater confidence.